Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest
J-NEURO
1 other identifier
interventional
468
1 country
28
Brief Summary
The SAVE-J NEUROTHERM trial is a cluster randomized trial that evaluated and compared the mortality risk, neurological outcomes, and adverse events between patients who underwent hypothermia and those who underwent normothermia after extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2025
Longer than P75 for not_applicable
28 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 3, 2025
CompletedStudy Start
First participant enrolled
January 6, 2025
CompletedFirst Posted
Study publicly available on registry
January 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
June 27, 2025
December 1, 2024
3 years
January 3, 2025
June 26, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Survival
At discharge (approximately 25 days)
Secondary Outcomes (3)
Survival
At 30 days, 90 days, and 1 year after admission
Neurological function: Cerebral performance categories (CPC)
At discharge (approximately 25 days), 30 days, 90 days, and 1 year after admission
Adverse events
During the intensive care unit stay, an average of 2 weeks
Study Arms (2)
Normothermia
ACTIVE COMPARATORTemperature control at 36 °C
Hypothermia
EXPERIMENTALTemperature control at 33-34 °C
Interventions
Procedure: Temperature control at 33-34 °C In the hypothermia group, patients receiving ECPR will be immediately cooled to 33ºC-34ºC with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be kept at 33ºC-34°C. The maintenance phase will end 24 h after reaching this targeted temperature. Subsequently, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.
Eligibility Criteria
You may qualify if:
- OHCA
- Age of 18-75 years, known or estimated
- An initial cardiac arrest rhythm of ventricular fibrillation/pulseless ventricular tachycardia or pulseless electrical activity
You may not qualify if:
- ECMO initiated after sustained return of spontaneous circulation (ROSC) and patients with sustained ROSC before ECMO initiation
- OHCA of presumed non-cardiac etiology
- Time from emergency call or witnessed arrest to hospital arrival of \>60 min
- Time from hospital arrival to ECMO initiation of \>60 min
- Pre-hospital ECPR
- Unavailability of the ECMO heat exchanger for temperature control
- Glasgow Coma Scale score before temperature control of \>8
- Core body temperature upon hospital arrival of ≤32ºC
- Surgical intervention before temperature control (e.g., surgical intervention for the primary disease or complications related to resuscitation/ECMO procedures)
- Do Not Attempt Resuscitation) order confirmed prior to temperature control
- Limitations in intensive care before temperature control
- Known cerebral performance category (CPC) of 3-4 before cardiac arrest
- Known chronic obstructive pulmonary disease with home oxygen therapy
- Known or suspected pregnancy
- Concomitant illness, such as malignancy, shortens life expectancy (180-day survival unlikely)
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (28)
Kurume University Hospital
Kurume, Fukuoka, 8300011, Japan
Asahikawa Medical University Hospital
Asahikawa, Hokkaido, 0788510, Japan
Sapporo Medical University Hospital
Sapporo, Hokkaido, 0608556, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, 0608648, Japan
Hyogo Prefectural Kakogawa Medical Center
Kakogawa, Hyōgo, 6758555, Japan
Hyogo Emergency Medical Center
Kobe, Hyōgo, 6510073, Japan
Toyooka Public Hospital
Toyooka, Hyōgo, 6688501, Japan
Kagawa University Hospital
Kita-gun, Kagawa-ken, 7610793, Japan
Oshima Prefectural Hospital
Amami, Kagoshima-ken, 8940015, Japan
Ebina General Hospital
Ebina, Kanagawa, 2430432, Japan
Saiseikai Yokohamashi Tobu Hospital
Yokohama, Kanagawa, 2308765, Japan
Kyoto Second Red Cross Hospital
Kyoto, Kyoto, 6028026, Japan
Tohoku University Hospital
Sendai, Miyagi, 9808574, Japan
Sendai Medical Center
Sendai, Miyagi, 9838520, Japan
Okayama University Hospital
Okayama, Okayama-ken, 7008558, Japan
Tsuyama Chuo Hospital
Tsuyama, Okayama-ken, 7080841, Japan
Okinawa Prefectural Nanbu Medical Center & Children's Medical Center
Shimajiri-gun, Okinawa, 9011193, Japan
Osaka Saiseikai Senri Hospital
Suita, Osaka, 5650862, Japan
Saitama Red Cross Hospital
Saitama, Saitama, 3308553, Japan
Tottori Prefectural Central Hospital
Tottori-shi, Tottori, 6800901, Japan
St. Luke's International Hospital
Tokyo, 1048560, Japan
Institute of Science Tokyo Hospital
Tokyo, 1138519, Japan
Nippon Medical School Hospital
Tokyo, 1138603, Japan
Tokyo Metropolitan Bokutoh Hospital
Tokyo, 1308575, Japan
Keio University Hospital
Tokyo, 1608582, Japan
Japanese Red Cross Musashino Hospital
Tokyo, 1808610, Japan
Tokyo Metropolitan Tama Medical Center
Tokyo, 1838524, Japan
National Hospital Organization Disaster Medical Center
Tokyo, 1900014, Japan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Akihiko Inoue
Hyogo Emergency Medical Center
- STUDY CHAIR
Yasuhiro Kuroda
Kagawa University
- STUDY CHAIR
Toru Hifumi
Kyorin University School of Medicine
- STUDY DIRECTOR
Tetsuya Sakamoto
Teikyo University
- STUDY DIRECTOR
Naoaki Ichihara
Osaka University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 3, 2025
First Posted
January 15, 2025
Study Start
January 6, 2025
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2028
Last Updated
June 27, 2025
Record last verified: 2024-12